Maddi Hebebrand, MC, Associate Editor

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

The agency shared details of additional voluntary recalls and its plans to release full results of its independent testing in the coming months.

This week, we feature top articles from our sister publications on updates in surgical management, diabetes control, and more.

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Explore the top headlines of the week including insights on the environmental impact of conferences, new clinical data, and the shift towards more natural-looking results.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Catch up on coverage from the first day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

In addition to Taylor, several other new leaders have been appointed to key roles within the AAD to help drive its mission of advancing dermatology.

Ahead of the annual meeting, Dermatology Times spoke with Draelos about why she looks forward to the meeting each year.

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

Serota and other field experts discussed best practices as well as new therapeutics.

Robinson shared insights into how the company is working to fight clinical research disparities.

Psoriasis trials are among the least diverse within dermatology, with participants predominantly being white men.

Research suggests that rebalancing the skin microbiome with pre-, post-, and probiotics may improve AD symptoms.

Single-use packaging and excess sample distribution contribute to environmental harm, necessitating a shift in industry practices.

Explore the top headlines of the week including insights from Terri Philips, MD, FAAP, innovations in wound healing, and more.

This week, we feature top articles from our sister publications on recent clinical trials, practice management, and innovative technology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the top headlines of the month including the expanding role of NPs and PAs, a guide to 2025 conferences, and expert insights from Paul Friedman, MD.

Today, Dermatology Times recognizes Rare Disease Day in an effort to amplify the voices of the over 300 million individuals affected by rare diseases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Objective tools like IGA and EASI provide structured severity assessment but often lack patient-reported insights such as itch severity.

Independent pharmacies are closing at high rates, leaving many communities without essential health care access.